Eatontown, NJ, March, 27 2017. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Calcium Acetate 667mg immediate-release tablets. This launch adds to Avet’s robust portfolio of generic oral solid products. Calcium Acetate is the AB rated generic equivalent to the phosphate binding drug Eliphos®. It is indicated to reduce serum phosphorus in patients with end stage renal disease. According to IMS data for the twelve-months ended January 2017, the U.S. market for Calcium Acetate 667mg immediate-release tablets is approximately $2.5 million.